Results 21 to 30 of about 23,676 (191)

Targeted therapy of RET fusion-positive non-small cell lung cancer

Frontiers in Oncology, 2022
Lung cancer has very high morbidity and mortality worldwide, and the prognosis is not optimistic. Previous treatments for non-small cell lung cancer (NSCLC) have limited efficacy, and targeted drugs for some gene mutations have been used in NSCLC with ...
Zixiong Shen, Binxu Qiu, Lin Li, Bo Yang, Guanghu Li   +4 more
doaj   +1 more source

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade [version 1; referees: 2 approved]

F1000Research, 2016
RET (REarranged during Transfection) is a receptor tyrosine kinase, which plays pivotal roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis.
Amanda J. Watson, Gemma V. Hopkins, Samantha Hitchin, Habiba Begum, Stuart Jones, Allan Jordan, Sarah Holt, H. Nikki March, Rebecca Newton, Helen Small, Alex Stowell, Ian D. Waddell, Bohdan Waszkowycz, Donald J. Ogilvie   +13 more
doaj   +1 more source

RET kinase inhibitors for -altered thyroid cancers

Therapeutic Advances in Medical Oncology, 2022
Precision oncology has opened a new era in cancer treatment focused on targeting specific cellular pathways directly involved in tumorigenesis. The REarrangement during Transfection ( RET ) proto-oncogene is involved in the pathogenesis of various ...
Danica M. Vodopivec, Mimi I. Hu
doaj   +1 more source

Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe

Frontiers in Oncology, 2023
The incidence of thyroid cancer is increasing worldwide with the disease burden in Europe second only to that in Asia. In the last several decades, molecular pathways central to the pathogenesis of thyroid cancer have revealed a spectrum of targetable ...
Rossella Elisei, Enrique Grande, Michael C. Kreissl, Sophie Leboulleux, Tarun Puri, Nicolas Fasnacht, Jaume Capdevila   +6 more
doaj   +1 more source

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness

Hepatology, EarlyView., 2022
Abstract Background and Aims Reliable noninvasive biomarkers are an unmet clinical need for the diagnosis of NASH. This study investigates the diagnostic accuracy of the circulating triggering receptor expressed on myeloid cells 2 (plasma TREM2) as a biomarker for NASH in patients with NAFLD and elevated liver stiffness.
Vineesh Indira Chandran, Charlotte Wilhelmina Wernberg, Mette Munk Lauridsen, Maria Kløjgaard Skytthe, Sofie Marchsteiner Bendixen, Frederik Tibert Larsen, Camilla Dalby Hansen, Lea Ladegaard Grønkjær, Majken Storm Siersbæk, Tina Di Caterino, Sönke Detlefsen, Holger Jon Møller, Lars Grøntved, Kim Ravnskjaer, Søren Kragh Moestrup, Maja Sofie Thiele, Aleksander Krag, Jonas Heilskov Graversen   +17 more
wiley   +1 more source

Anti-epidermal growth factor vaccine antibodies increase the antitumor activity of kinase inhibitors in ALK and RET rearranged lung cancer cells

Translational Oncology, 2021
Advanced NSCLC patients harboring EML4-ALK and CCDC6-RET rearrangements derive benefit from treatment with ALK and RET TKIs but not immune checkpoint inhibitors.
Jordi Codony-Servat, Silvia García-Roman, Miguel Ángel Molina-Vila, Jordi Bertran-Alamillo, Santiago Viteri, Erik d'Hondt, Rafael Rosell   +6 more
doaj   +1 more source

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

ESMO Open, 2020
Purpose The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET ...
Jessica Lee, Vivek Subbiah, Shuang Liu, Jason Roszik, David Hong, Funda Meric-Bernstam, John Heymach, Ramona Dadu, Kenneth Hess, Le Huang, Aparna Hegde, Alexander Y Andreev-Drakhlin, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Elizabeth G Grubbs, Siraj M Ali, Yasir Y Elamin, George R Simon, George R Blumenschein, Jr, Vassiliki A Papadimitrakopoulou   +21 more
doaj   +1 more source

Molecular Testing and Treatment Strategies in RET-Rearranged NSCLC Patients: Stay on Target to Look Forward

Journal of Molecular Pathology, 2022
RET alterations are recognized as key oncogenic drivers in different cancer types, including non-small cell lung cancer (NSCLC). Multikinase inhibitors (MKIs) with anti-RET activities resulted in variable efficacy with significant toxicities because of ...
Maria Lucia Reale, Valentina Bertaglia, Angela Listì, Silvia Novello, Francesco Passiglia   +4 more
doaj   +1 more source

Non-small-cell lung cancer: how to manage RET-positive disease

Drugs in Context, 2022
Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically observed in about 1–2% of NSCLC, resulting in constitutive activation of downstream signalling ...
Elisa Andrini, Mirta Mosca, Linda Galvani, Francesca Sperandi, Biagio Ricciuti, Giulio Metro, Giuseppe Lamberti   +6 more
doaj   +1 more source

Expert consensus on the diagnosis and treatment of RET gene fusion non‐small cell lung cancer in China

Thoracic Cancer, 2023
The rearranged during transfection (RET) gene is one of the receptor tyrosine kinases and cell‐surface molecules responsible for transmitting signals that regulate cell growth and differentiation.
Xingxiang Pu, Chunwei Xu, Qian Wang, Wenxian Wang, Fang Wu, Xiuyu Cai, Zhengbo Song, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Long Huang, Jingping Yuan, Zhansheng Jiang, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Xuewen Liu, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Weiwei Pan, Fei Pang, Jintao Huang, Kai Wang, Fan Wu, Tingting Shen, Shirui Zou, Bingwei Xu, Liping Wang, Youcai Zhu, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jing Kang, Jiatao Zhang, Chao Zhang, Jianfei Fu, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Dong Wang, Zhaofeng Wang, Yue Hao, Zhen Wang, Bing Wan, Donglai Lv, Gang Lan, Shengjie Yang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Yuan Li, Zhefeng Liu, Nong Yang, Huijuan Wang, Wenbin Huang, Zhuan Hong, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Xixu Zhu, Yi Shen, Yiping Zhang, Shenglin Ma, Yong Song, Yuanzhi Lu, Wenfeng Fang, Ziming Li, Lin Wu   +102 more
doaj   +1 more source